The number of items recalled on the STM-COMET delayed verbal recall tests showed a significant increase in the group switched to RLAI

(p < 0.05). The mean response time (seconds) in the STM-COMET memory scanning test was a significant improvement, and the mean number of items recalled on the STM-COMET memory filtering test was a significant increase in the group switched to RLAI (p = 0.003 and 0.02, respectively). Furthermore, no significant differences were seen in the mean changes from baseline in each of the STM-COMET Inhibitors,research,lifescience,medical tests in the control group. No significant difference was seen between the two groups in the mean change from baseline in the selleck chem risperidone equivalent dose. The mean change from baseline in the biperiden equivalent dose was Inhibitors,research,lifescience,medical significantly lower in the group switched to RLAI than in the control group (Table 3). The mean risperidone equivalent dose and the mean biperiden equivalent dose were a significant decrease from baseline in the group switched to RLAI (p = 0.04 and 0.01, respectively). No significant differences were observed

in the control Inhibitors,research,lifescience,medical group either in the mean change from baseline in the risperidone equivalent dose or in the mean change from baseline in the biperiden equivalent dose. Table 3. The change over time in the risperidone equivalent dose and the biperiden equivalent dose (mg/day) Table 4 shows correlations between changes in cognitive function and clinical symptoms before Inhibitors,research,lifescience,medical and after switching to RLAI. Most improvements in cognitive function were not selleck compound correlated with clinical symptoms. Only the improvement in the delayed verbal recall was significantly correlated

with changes in the PANSS positive symptoms. Table 4. Correlations between changes in cognitive and clinical outcomes before and after switching risperidone long-acting injection Discussion No differences were seen in efficacy in the improvement of clinical symptoms between the group switched to RLAI and the control group when inpatients with schizophrenia were given RLAI for 24 weeks, and the efficacy thereof with respect to clinical Inhibitors,research,lifescience,medical symptoms was compared with that obtained in the control group, which continued to receive oral risperidone. In addition, although Cilengitide no significant differences were seen between the two groups in the change in risperidone equivalent dose, the risperidone equivalent dose could be reduced in the group switched to RLAI more than in the control group. In overseas clinical studies, switching to RLAI has also been seen to result in lower doses [Schmauss et al. 2007]. Furthermore, as described above, considering that it was possible to strive for perfect treatment compliance in this study, switching patients from oral risperidone to RLAI might result in the same clinical efficacy as that achieved with oral risperidone, even if the risperidone equivalent dose is lower than that used with oral risperidone.